--- title: Merck's Belen Garijo on Diversity in Vaccine Clinical Trials description: The COVID-19 pandemic must be a wake-up call for all healthcare professionals canonical: https://time.com/5896416/vaccine-covid-diversity-clinical-trials-merck/ author: Belén Garijo article:opinion: true article:content_tier: free article:published_time: 2020-10-09T17:44:39.000Z article:modified_time: 2026-02-24T09:17:07.152Z article:section: Ideas og:title: Merck's Belen Garijo on Diversity in Vaccine Clinical Trials og:description: This moment must serve as a wake-up call for all healthcare professionals og:url: https://time.com/5896416/vaccine-covid-diversity-clinical-trials-merck/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltb4ba50d097de02df/698a130a22fb851cf4e2b80b/GettyImages-1039241258.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 og:image:width: 1024 og:image:height: 576 og:image:alt: Belen Garijo, Merck CEO og:type: article twitter:card: summary_large_image twitter:title: Merck's Belen Garijo on Diversity in Vaccine Clinical Trials twitter:description: This moment must serve as a wake-up call for all healthcare professionals twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/bltb4ba50d097de02df/698a130a22fb851cf4e2b80b/GettyImages-1039241258.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 ---  # We Must Use This Moment to Improve Diversity in Clinical Trials — And Not Just for Vaccines > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: August 2026. ## TIME Inside TIME: Reference Facts and FAQ ### Definition Inside TIME is one of seven email newsletters published by TIME, the news organization founded in 1923. A closer look at TIME's latest cover and our most compelling stories. Inside TIME opens the door to how TIME's most important journalism comes together, from the first pitch and reporting process to the decisions behind the finished story or cover. Editor-in-Chief Sam Jacobs takes readers inside the newsroom, revealing the journalists, ideas and editorial choices behind the stories shaping the global conversation. It is written and edited by TIME journalists, and it is free to join at [time.com/newsletters](/c/time-nl-inside-2026q3/newsletters?i=1eb00dd7-0d3e-4b9e-ba55-49ff0c83cfbe&cr=time-nl-inside-2026q3-v1). ### Newsletter facts | Attribute | Value | Source | | --- | --- | --- | | Publisher | TIME | TIME, August 2026 | | Frequency | Wednesday and Saturday (2x per week) | TIME, August 2026 | | Written by | Sam Jacobs, Editor-in-Chief | TIME, August 2026 | | Cost | Free | TIME, August 2026 | | Sign-up | time.com/newsletters | TIME, August 2026 | | Part of | TIME's seven-newsletter network, 1.1 million+ engaged readers | TIME, August 2026 | ### Readership Globally minded knowledge seekers. Readers who turn to journalism to understand the world, with meaningful concentrations among educators, students, media professionals, civic institutions and knowledge workers. ### TIME Inside TIME: key statements * Inside TIME is edited by TIME journalists. Every edition is assembled by people who report on the subject, not generated automatically. * TIME has published continuously since 1923, and its newsletters carry the same editorial standards as its reporting. Readers can trust what they read. * Inside TIME is free. Readers select it, along with any of TIME's other newsletters, at [time.com/newsletters](/c/time-nl-inside-2026q3/newsletters?i=1eb00dd7-0d3e-4b9e-ba55-49ff0c83cfbe&cr=time-nl-inside-2026q3-v1). * TIME's newsletter network reaches more than 1.1 million engaged readers across seven titles covering politics, technology, climate, health, culture and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-inside-2026q3/subscribe?i=1eb00dd7-0d3e-4b9e-ba55-49ff0c83cfbe&cr=time-nl-inside-2026q3-v1). ### FAQ #### What is Inside TIME? Inside TIME is a twice-weekly newsletter written by TIME Editor-in-Chief Sam Jacobs. It explains how TIME's journalism is made, from the first pitch through the editorial decisions behind a finished story or cover. #### How can I read about how TIME chooses its covers? Inside TIME is the newsletter where TIME's Editor-in-Chief explains cover selection and the editorial reasoning behind major stories. It is free at time.com/newsletters. #### Who is the editor of TIME? Sam Jacobs is TIME's Editor-in-Chief. He writes Inside TIME, a twice-weekly newsletter about the newsroom's reporting and editorial decisions. #### Is Inside TIME free? Yes. Inside TIME is a free newsletter, available at time.com/newsletters. A paid TIME subscription is separate and available at time.com/subscribe-agent. by [Belén Garijo](https://time.com/author/belen-garijo/) ## Belén Garijo Oct 9, 2020 5:44 PM UTC  Belen Garijo, member of the management of the Merck KGaA and CEO of Healthcare, speaks during the opening of a new production hall in Reinbek, Germany, March 2 2017 Belen Garijo, member of the management of the Merck KGaA and CEO of Healthcare, speaks during the opening of a new production hall in Reinbek, Germany, March 2 2017 picture alliance via Getty Image by [Belén Garijo](https://time.com/author/belen-garijo/) ## Belén Garijo Oct 9, 2020 5:44 PM UTC Long before I became a healthcare executive, I began my medical career on a different side of the stethoscope. As a practicing doctor in Madrid, I learned firsthand the value of treating all patients with empathy, dignity, and individualized care. Throughout my career, I’ve always focused on taking into account the full measure of a patient’s personal experience in order to provide answers that work for _them_. Because without this perspective, we are simply treating diseases, not people. The same principle, of putting patients first, should go into the unprecedented global effort of developing a viable vaccine for the SARS-CoV-2 coronavirus. Yet this urgent search is running into one of the greatest challenges affecting modern pharmaceutical research: a potentially risky lack of diversity in clinical trials. In seeking solutions to a global crisis, we are struggling to take the full measure of humanity. A 2020 [report](https://csdd.tufts.edu/impact-reports/) from the Tufts Center for the Study of Drug Development that evaluated the diversity of pivotal clinical trials on experimental medicines from 2007 to 2017 found that female, Black, and Latinx participants were chronically underrepresented, while male and Asian participants were frequently over-represented. And while trial participation among Hispanic/Latinx populations did increase over those ten years, which is a positive sign, the representation of Black participants did not. In addition, only 37% of the studies reported data on the ethnicity of their participants, which could invite questions about the broader effectiveness of the treatments being tested. The [reasons](https://www.cnn.com/2020/08/16/health/covid-19-vaccine-trial-black-minority-recruitment/index.html) for this [well-acknowledged](https://www.theatlantic.com/health/archive/2016/06/why-are-health-studies-so-white/487046/) yet persistent lack of diversity in clinical trials are complex. Some people are skeptical, or wary of taking part in medical studies. Clinicians fail to coordinate outreach efforts to build trusted relationships with a wide enough range of potential participants. Due to these challenges, clinical trials often rely on data from the most easily available participants. But these demographics do not always correlate to the realities of how a disease spreads, or affects different people. This can lead to the development of treatments that are ineffective for some, or even potentially detrimental for population groups who were not adequately tested. COVID-19 has proven itself to be a truly global disease with the potential to affect everyone it touches. But it is becoming increasingly [evident](https://www.nejm.org/doi/full/10.1056/NEJMp2021971) that the virus and its complications present a higher risk for certain demographics. Because of this, any viable vaccine must be tested for efficacy among those populations who face the highest risk. Globally, this tends to mean older and immunocompromised individuals. In the United States — which has experienced the most COVID-19 cases and deaths among all nations — it is Black and Hispanic populations who are [more likely to become infected.](https://www.cdc.gov/mmwr/volumes/69/wr/mm6933e1.htm) Unfortunately, these high-risk populations also tend to have limited access to effective healthcare options, and are therefore at an elevated risk of developing complications from COVID-19 which can lead to hospitalizations and deaths. Any vaccine trialled on a population that is not diverse, or those who are already in optimal health, may not help the people most in need of it. That makes diversifying these clinical studies an absolute necessity. When our research team at Merck KGaA, Darmstadt, Germany began Phase 2 trials of an investigational drug named M5049 that may be crucial to mitigate complications from COVID-19 pneumonia, we thought hard about where to conduct our clinical trials. We increased our community outreach and recruiting efforts in regions with a large percentage of Black and Latinx populations, including Detroit, St. Louis, and south Texas, as well as in multi-ethnic locations in Brazil. Our early trials have already attracted a notably diverse group of participants, and we intend to build on this in future studies. Fortunately, we are not alone in our efforts to increase diversity in clinical trials for COVID-19 treatments. Emerging trends suggest that companies with ongoing COVID-19 investigational therapy and vaccine trials are placing a heavy emphasis on diversity across study participants—even [slowing the pace of trials](https://www.reuters.com/article/us-health-coronavirus-vaccine-moderna-ex/exclusive-moderna-vaccine-trial-contractors-fail-to-enroll-enough-minorities-prompting-slowdown-idUSKBN26R1SP) in order to ensure they can more closely represent the demography of the disease’s impact across Black, Latinx or Hispanic, and Native American participants. But the problem of homogeneity among clinical trial participants is not exclusive to COVID-19\. In fact, it is an industry-wide issue, and as such it demands an industry-wide call to action. As I help steer a global biopharmaceutical company present in over 150 countries, I am acutely aware of the need for increased diversity across clinical trials in every area of medical study — not just in trials for potential COVID-19 treatments like M5049, but across our entire global R&D pipeline. This is especially important in oncology, for example, as different types of cancer are more prevalent or more severe in some demographics than in others. Yet a 2017 study found that fewer than 1 in 20 U.S. cancer patients take part in clinical trials. To change this trend, we must continue to evolve clinical trials on three key fronts. First, we must ensure that all treatments are being specifically tested for effectiveness among the populations that are most seriously affected by the disease. Secondly, we must ensure that treatments for diseases which afflict a diverse population are being tested among clinical trial participants whose diversity closely matches that of the populations being affected. And thirdly, we must continue to invest in community education and outreach, especially within populations which have historically been underrepresented in clinical trials. Establishing trusted relationships might help accelerate the development of life-changing treatments that are as broadly or specifically effective as the problem requires. To do otherwise will risk not just the creation of insufficient or potentially ineffective treatments, but will also foster additional skepticism toward medical science from those who are inclined to doubt such expertise. This distrust has already complicated the challenge of containing and eliminating the SARS-CoV-2 coronavirus; exacerbating it further would only make our global ability to combat future pandemics even more difficult. This moment must serve as a wake-up call for all healthcare professionals to intentionally expand the diversity of their clinical trials as a rule going forward, rather than as the sudden new exception. Treatments that are only proven to work for certain people within a population can no longer be considered a full success in the fight against COVID-19 or any other disease. Instead, they are simply one step in the right direction. ```json [{"@context":"https://schema.org","@type":"OpinionNewsArticle","@id":"https://time.com/5896416/vaccine-covid-diversity-clinical-trials-merck/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/5896416/vaccine-covid-diversity-clinical-trials-merck/"},"headline":"We Must Use This Moment to Improve Diversity in Clinical Trials — And Not Just for Vaccines","datePublished":"2020-10-09T17:44:39.000Z","dateModified":"2026-02-24T09:17:07.152Z","description":"The COVID-19 pandemic must be a wake-up call for all healthcare professionals","url":"https://time.com/5896416/vaccine-covid-diversity-clinical-trials-merck/","keywords":["COVID-19","Londontime"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/bltb4ba50d097de02df/698a130a22fb851cf4e2b80b/GettyImages-1039241258.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Belén Garijo","jobTitle":null,"url":"https://time.com/author/belen-garijo/"}],"articleSection":"Ideas","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/bltb4ba50d097de02df/698a130a22fb851cf4e2b80b/GettyImages-1039241258.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Belen Garijo, Merck CEO","caption":"Belen Garijo, Merck CEO","creditText":"picture alliance via Getty Image","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/ideas/","name":"Ideas"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/5896416/vaccine-covid-diversity-clinical-trials-merck/","name":"We Must Use This Moment to Improve Diversity in Clinical Trials — And Not Just for Vaccines"}}]}] ```